A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News

Simply Wall St.

05/05

Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2633911857"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633911857\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633911857?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-05-05 18:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633911857","market":"nz","top_or_hot":-1,"title":"A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News","media":"Simply Wall St.","content":"<div>\n<p>Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-05-05 18:23</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1","article_id":"2633911857","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/a-look-at-indivior-pharmaceuticals-nasdaqgsindv-valuation-af-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633911857","pubTimestamp":1777976589,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase plan.\nSee our latest analysis for Indivior Pharmaceuticals.\nThe recent Q1 beat, raised 2026 guidance, and the new accelerated share repurchase agreement have all coincided with strong momentum, with a 27.93% 1 month share price return and a very large 1 year total shareholder return that far...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INDV":"INDIVIOR PLC"},"translate_title":"Indivior Pharmaceuticals（纳斯达克GS：INDV）第一季度估值超出预期、2026年指引上调和回购消息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INDV":1.5},"content_text":"Indivior Pharmaceuticals (INDV) is back on investors' radars after a busy stretch that combined strong Q1 2026 results, a raised full year revenue outlook, and a fresh accelerated share repurchase plan. See our latest analysis for Indivior Pharmaceuticals. The recent Q1 beat, raised 2026 guidance, and the new accelerated share repurchase agreement have all coincided with strong momentum, with a 27.93% 1 month share price return and a very large 1 year total shareholder return that far outpaces typical market levels. If Indivior’s run has you looking for the next opportunity in healthcare and biotech, it could be a good time to scan 33 healthcare AI stocks. With earnings, guidance, and buybacks all moving in the same direction, Indivior now trades at what some models suggest is a sizeable intrinsic discount. This raises the question: is there still a buying opportunity here, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 3% Overvalued The most followed valuation narrative puts Indivior’s fair value at $37.86, slightly below the last close of $38.98, which suggests a modest premium today.  The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.  Read the complete narrative. Want to see what kind of revenue trajectory and margin profile has to materialize to back that fair value, including how much earnings power the narrative is baking in and what sort of valuation multiple it assumes on those future profits? Result: Fair Value of $37.86 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, if SUBLOCADE adoption, the Move Forward in Recovery campaign, and the Indivior Action Agenda outperform current assumptions, earnings and valuation could outpace this slightly overvalued narrative. Find out about the key risks to this Indivior Pharmaceuticals narrative. Another Angle on Value The analyst narrative suggests Indivior is about 3% overvalued around $37.86, yet our DCF model points the other way. On that view, the stock at $38.98 sits roughly 64% below an estimated future cash flow value of $108.90. Which story do you rely on more: the earnings multiple or the cash flow math? Look into how the SWS DCF model arrives at its fair value. INDV Discounted Cash Flow as at May 2026Next Steps With sentiment clearly mixed between upside potential and real concerns, this is the moment to review the data yourself and move quickly to form a view using 4 key rewards and 3 important warning signs Looking for more investment ideas? Do not stop with a single stock story. Widen your opportunity set now using focused stock lists that highlight different strengths investors often look for.  Target dependable cash generators by scanning companies with strong income potential and resilient payouts through 12 dividend fortresses. Spot quality at a discount by checking stocks that combine robust fundamentals with attractive pricing using the screener containing 25 high quality undiscovered gems. Prioritize sleep at night holdings by focusing on companies with steadier profiles and lower risk markers via the 70 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}